Pirfenidone improves survival in IPF: Results from a real-life study

BMC Pulmonary Medicine

Volumn 18, Issue 1, 2018, Pages

  Margaritopoulos, George A ^a,b   Trachalaki, Athina ^a   Wells, Athol U ^b   Vasarmidi, Eirini ^a   Bibaki, Eleni ^a   Papastratigakis, George ^a   Detorakis, Stathis ^a   Tzanakis, Nikos ^a   Antoniou, Katerina M ^a  

^a UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

^b ROYAL BROMPTON HOSPITAL   (United Kingdom)

Author keywords

IPF; Pirfenidone; Real life; Survival

Indexed keywords

PIRFENIDONE; NONSTEROID ANTIINFLAMMATORY AGENT; PYRIDONE DERIVATIVE;

ADVERSE EVENT; AGED; ARTICLE; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DEMOGRAPHY; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FIBROSING ALVEOLITIS; FORCED VITAL CAPACITY; GASTROINTESTINAL SYMPTOM; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY RATE; OBSERVATIONAL STUDY; PHOTOSENSITIVITY; RETROSPECTIVE STUDY; SURVIVAL ANALYSIS; SURVIVAL RATE; DISEASE EXACERBATION; GREECE; MIDDLE AGED; MORTALITY; TIME FACTOR; TREATMENT OUTCOME; VERY ELDERLY; VITAL CAPACITY;

AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DISEASE PROGRESSION; FEMALE; GREECE; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; MALE; MIDDLE AGED; PYRIDONES; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TIME FACTORS; TREATMENT OUTCOME; VITAL CAPACITY;

EID: 85057112940     PISSN: None     EISSN: 14712466     Source Type: Journal    
DOI: 10.1186/s12890-018-0736-z     Document Type: Article

References (25)

1. Margaritopoulos GA, Romagnoli M, Poletti V, Siafakas NM, Wells AU, Antoniou KM. Recent advances in the pathogenesis and clinical evaluation of pulmonary fibrosis. Eur Respir Rev. 2012;21:48-56.
2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66(1):7-30.
3. Hutchinson J, Fogarty A, Hubbard R, McKeever T. Global incidence and mortality of idiopathic pulmonary fibrosis: a systematic review. Eur Respir J. 2015;46(3):795-806.
4. Margaritopoulos GA, Vasarmidi E, Antoniou KM. Pirfenidone in the treatment of idiopathic pulmonary fibrosis: an evidence-based review of its place in therapy. Core Evidence. 2016;11:11-22.
5. Raghu G, Rochwerg B, Zhang Y, Garcia CA, Azuma A, Behr J, Brozek JL, Collard HR, Cunningham W, Homma S, et al. An official ATS/ERS/JRS/ALAT clinical practice guideline: treatment of idiopathic pulmonary fibrosis. An update of the 2011 clinical practice guideline. Am J Respir Crit Care Med. 2015;192(2):e3-19.
6. King TE Jr, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, Gorina E, Hopkins PM, Kardatzke D, Lancaster L, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2083-92.
7. Nathan SD, Albera C, Bradford WZ, Costabel U, Glaspole I, Glassberg MK, Kardatzke DR, Daigl M, Kirchgaessler KU, Lancaster LH, et al. Effect of pirfenidone on mortality: pooled analyses and meta-analyses of clinical trials in idiopathic pulmonary fibrosis. Lancet Respir Med. 2017;5(1):33-41.
8. Wells AU, Behr J, Costabel U, Cottin V, Poletti V, Richeldi L. Hot of the breath: mortality as a primary end-point in IPF treatment trials: the best is the enemy of the good. Thorax. 2012;67(11):938-40.
9. Costabel U, Albera C, Lancaster LH, Lin CY, Hormel P, Hulter HN, Noble PW. An open-label study of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis (RECAP). Respiration. 2017;94(5):408-15.
10. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, Colby TV, Cordier JF, Flaherty KR, Lasky JA, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183(6):788-824.
11. Margaritopoulos GA, Antoniou KM, Wells AU. Comorbidities in interstitial lung diseases. Eur Respir Rev. 2017;26(143):160027.
12. Mura M, Porretta MA, Bargagli E, Sergiacomi G, Zompatori M, Sverzellati N, Taglieri A, Mezzasalma F, Rottoli P, Saltini C, et al. Predicting survival in newly diagnosed idiopathic pulmonary fibrosis: a 3-year prospective study. Eur Respir J. 2012;40(1):101-9.
13. Wells AU, Desai SR, Rubens MB, Goh NS, Cramer D, Nicholson AG, Colby TV, du Bois RM, Hansell DM. Idiopathic pulmonary fibrosis: a composite physiologic index derived from disease extent observed by computed tomography. Am J Respir Crit Care Med. 2003;167(7):962-9.
14. Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, Cottin V, Flaherty KR, Hansell DM, Inoue Y, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2071-82.
15. Raghu G, Wells AU, Nicholson AG, Richeldi L, Flaherty KR, Le Maulf F, Stowasser S, Schlenker-Herceg R, Hansell DM. Effect of nintedanib in subgroups of idiopathic pulmonary fibrosis by diagnostic criteria. Am J Respir Crit Care Med. 2017;195(1):78-85.
16. Wells AU. Efficacy data in treatment extension studies of idiopathic pulmonary fibrosis: interpret with caution. Lancet Respir Med. 2018; [Epub ahead of print].
17. Raghu G, Anstrom KJ, King TE Jr, Lasky JA, Martinez FJ. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med. 2012;366(21):1968-77.
18. Fisher M, Nathan SD, Hill C, Marshall J, Dejonckheere F, Thuresson PO, Maher TM. Predicting life expectancy for pirfenidone in idiopathic pulmonary fibrosis. J Manag Care Spec Pharm. 2017;23(3-b Suppl):S17-s24.
19. Collet JP, Montalescot G, Steg PG, Steinhubl SR, Fox KA, Hu TF, Johnston SC, Hamm CW, Bhatt DL, Topol EJ. Clinical outcomes according to permanent discontinuation of clopidogrel or placebo in the CHARISMA trial. Arch Cardiovasc Dis. 2009;102(6-7):485-96.
20. Calverley PM, Spencer S, Willits L, Burge PS, Jones PW. Withdrawal from treatment as an outcome in the ISOLDE study of COPD. Chest. 2003;124(4):1350-6.
21. Vestbo J, Anderson Julie A, Calverley Peter Mark A, Celli B, Ferguson Gary T, Jenkins C, Yates Julie C, Jones Paul W. Bias due to withdrawal in long-term randomised trials in COPD: evidence from the TORCH study. Clin Respir J. 2010;5(1):44-9.
22. Noble PW, Albera C, Bradford WZ, Costabel U, Glassberg MK, Kardatzke D, King TE Jr, Lancaster L, Sahn SA, Szwarcberg J, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet (London, England). 2011;377(9779):1760-9.
23. Salih GN, Shaker SB, Madsen HD, Bendstrup E. Pirfenidone treatment in idiopathic pulmonary fibrosis: nationwide Danish results. Eur Clin Respir J. 2016;3. https://doi.org/10.3402/ecrj.v3403.32608.
24. Hughes G, Toellner H, Morris H, Leonard C, Chaudhuri N. Real world experiences: pirfenidone and nintedanib are effective and well tolerated treatments for idiopathic pulmonary fibrosis. J Clin Med. 2016;5(9):78.
25. Tzouvelekis A, Karampitsakos T, Ntolios P, Tzilas V, Bouros E, Markozannes E, Malliou I, Anagnostopoulos A, Granitsas A, Steiropoulos P, et al. Longitudinal "real-world" outcomes of pirfenidone in idiopathic pulmonary fibrosis in Greece. Front Med. 2017;4:213.